Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies

Séan M. O’Cathail(Imperial College London), Roshan Agarwal(Imperial College Healthcare NHS Trust), Karen Carty(Cancer Research UK Clinical Trials Unit), Janice S. Kwon, Roekshana Shaboodien(Hammersmith Hospital), Hani Gabra(Royal Children's Hospital), Sarah Mahmoud(Desert Research Center), Sarah P. Blagden(Churchill Hospital), Sue Whear(Imperial College Healthcare NHS Trust), Patrick O’Sullivan(Imperial College Healthcare NHS Trust)
International Journal of Gynecological Cancer
August 1, 2013
10.1097/igc.0b013e31829f1799
Cited by 16

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201